Efficacy and safety of mesenchymal stromal cells of bone marrow in patients with refractory forms Crohn's disease

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The aim of our study was to assess the safety and medium-term efficacy of biological therapy of Crohn’s disease — the transplantation of allogeneic bone marrow multipotent mesenchymal stromal cells (MMSC) and anticytokine therapy with selective immunosuppressants. All patients with Crohn’s disease (chronic continuous and chronic relapsing disease) were divided into two groups depending on the method of therapy: group 1 patients (n = 30) who that mesenchymal stromal cells (MSCs) were administered twice a month at intervals of 1 week, and then every 6 months Group 2 patients (n = 20) received infliximab (inflation) by the scheme 0-2-6 (induction therapy), then every 8 weeks (maintenance therapy) for at least the year. The age of patients in all groups ranged from 19 to 56 years (median (Me) — 36 years), the majority of patients were women — 28 (56.0%). Disease duration ranged from 3 to 15 years (Me — 5 years). Date of administration or cell culture is a point of inclusion in a clinical study. In analyzing the results, it was found that both methods of biological therapy refractory forms of CD can achieve clinical and, in some cases, endoscopic remission. Preservation of clinical remission is achieved in most cases without steroids. Thus, both methods are comparable biological therapy on outcome. Transplantation of bone marrow MSCs can be considered as a promising and safety method for treatment of refractory Crohn’s disease, comparable to treatment with infliximab.

Full Text

Restricted Access

About the authors

O. V Knyazev

Central Research Institute of Gastroenterology, Moscow

A. I Parfenov

Central Research Institute of Gastroenterology, Moscow

P. L Shcherbakov

Central Research Institute of Gastroenterology, Moscow

I. N Ruchkina

Central Research Institute of Gastroenterology, Moscow

S. G Khomeriki

Central Research Institute of Gastroenterology, Moscow

A. G Konoplyannikov

Medical Radiological Research Center, Obninsk

References

  1. Crohn B.B., Ginzburg L., Oppenheimer G.D. Regional ileitis; a pathologic and clinical entity. J. Amer. Med. Assoc. 1932; 99: 1323—9.
  2. Белоусова Е.А. Реальные и потенциальные возможности лечения рефрактерных форм воспалительных заболеваний кишечника. Рус. мед. журн. 2005; 2: 88—95.
  3. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115(1): 182—205.
  4. Malchow H., Ewe K., Brandes J.W. et al. European cooperative Crohn's disease study (ECCDS): results of drug treatment. Gastroenterology 1984; 86: 249—66.
  5. Summers R.W., Switz D.M., Sessions J.T. et al. National cooperative Crohn's disease study group: results of drug treatment. Gastroenterology 1979; 77: 847—69.
  6. Faubion W.A., Loftus E.V., Harmsen W.S. et all. The natural history of corticosteroid therapy for inflammatory bowel disease: a population based study. Gastroenterology 2001; 121: 255—60.
  7. Breedveld F.C. Therapeutic monoclonal antibodies. Lancet 2000; 355: 735—40.
  8. Rutgeerts P., Feagan B.G., Lichtenstein G.R. et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126: 402—13.
  9. Wayne G. Overview of stem cell therapy for Crohn's disease. Expert. Opin. Biol. Ther. 2009; 9(7): 841—7.
  10. Распоряжение Правительства РФ от 28.12.2012 №2580-р «Об утверждении Стратегии развития медицинской науки в РФ на период до 2025 года».
  11. Chapel A., Bertho J.M., Bensidhoum M. et al. Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome. J. Gene Med. 2003; 5: 1028—38.
  12. Krampera M., Glennie S., Dyson J. et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003; 101: 3722—29.
  13. Uccelli A., Pistoia V., Moretta L. Mesenchymal stem cells: a new strategy for immunosuppression? Trends Immunol. 2007; 28: 219-26.
  14. Abdi R., Fiorina P., Adra C.N. et al. Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes 2008; 57: 1759-67.
  15. Meisel R., Zibert A., Laryea M. et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indolamine 2,3-dioxygenase-mediated tryptophan degredation. Blood 2004; 103: 4619-21.
  16. Rabinovitch A., Suarez-Pinzon W.L. Role of cytokines in the pathogenesis of autoimmune diabetes mellitus. Rev. Endocr. Metab. Disord. 2003; 4(3): 291-9.
  17. Drakos P.E., Nagler A., Or R. Case of Crohn’s disease in bone marrow transplantation. Am. J. Hematol. 1993; 43: 157-8.
  18. Molendijk I., Duijvestein M., van der Meulen-de A.E. et al. Immunomodulatory effects of mesenchymal stromal cells in Crohn’s disease. J. Allergy 2012; 2012: 187408.
  19. Best W.R., Becktel J.M., Singleton J.W. et al. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology 1976; 70(3): 439-40.
  20. Sandborn W.J, Feagan B.G, Hanauer S.B. et al. А review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology 2002; 122: 512-30.
  21. Цыб А.Ф., Коноплянников А.Г., Колесникова А.И. и др. Получение и использование в медицине клеточных культур из мезенхимальных стволовых клеток костного мозга человека. Вестник Российской Академии медицинских наук 2004; 59(9): 71- 6.
  22. Lalu M.M., McIntyre L., Pugliese C. et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One 2012; 7(10): e47559.
  23. Oyama Y., Traynor A.E., Barr W. et al. Allogeneic stem cell transplantation for autoimmune diseases: nonmyeloablative conditioning regimens. Bone Marrow Transplant. 2003; 32 Suppl 1: S81-3.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: 

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies